GlassScriptPhysician profile
Mary K Hire
NPI 1265629935
$11,020.39
in general payments reported to CMS, 2019-2025
30 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,079 · 2022: $1,755 · 2023: $3,003 · 2024: $2,921 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,026 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,026.21 |
| Education | $160.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,833.22 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $2,452.97 | 2021-2025 | |
| Janssen Biotech, INC. | $702.62 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $527.88 | 2022-2025 | |
| Qol Medical, LLC | $502.74 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $419.66 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $417.32 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $376.37 | 2022-2024 | Linzess |
| Ardelyx, INC. | $303.15 | 2022-2025 | Ibsrela |
| Celgene Corporation | $277.82 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $247.05 | 2024-2025 | Omvoh |
| Vivus LLC | $211.33 | 2021-2023 | Qsymia |
| Nestle Healthcare Nutrition INC. | $200.01 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $187.64 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $179.11 | 2022-2024 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $178.19 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $167.76 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $162.66 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Evoke Pharma, INC. | $126.12 | 2021-2024 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $120.39 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $101.22 | 2021-2024 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $67.54 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $55.29 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.24 | 2023 | Cyltezo |
| Pfizer INC. | $39.94 | 2023-2025 | |
| Medtronic, INC. | $37.91 | 2024 | Interstim |
| Novo Nordisk INC | $29.48 | 2025 | Wegovy |
| Amgen INC. | $17.94 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $16.43 | 2023 | Terlivaz |
| Celltrion USA INC. | $15.39 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.